Business
Kalytera Announces Second US Patent for Prevention and Treatment of Graft Versus Host Disease
Kalytera Announces Second US Patent for Prevention and Treatment of Graft Versus Host Disease.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\n \n Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the \"Company\" \n or \"Kalytera\") announced today that it has received a Notice \n of Allowance from the United States Patent and Trademark Office for a \n second patent covering the use of cannabidiol (\"CBD\") in the \n prevention and treatment of graft versus host disease (\"GVHD\").\n \n \n \"We are delighted to receive this additional patent allowance from the \n USPTO,\" said Robert Farrell, Kalytera's Chief Executive Officer. \"This \n allowance is for our US Patent Application 14/787,515. Two weeks ago, we \n announced that we had received a Notice of Allowance for our US Patent \n Application 15/143,694. We now have two allowed US patents, which \n together cover both the prevention and treatment of GVHD. Kalytera has \n exclusive world-wide rights to the technology covered by both of these \n patents.\"\n \n \n Mr. Farrell continued, \"We are now positioned to move forward with our \n program to obtain FDA approval of CBD in the prevention of GVHD. The \n next step in this process will be the initiation of a Phase 2 clinical \n study designed to assess the pharmacokinetic and safety profiles of \n multiple doses of CBD, and we anticipate that this study will begin \n prior to year-end.\"\n \n \n Kalytera’s Phase 2 study is expected to enroll 36 patients following \n allogeneic hematopoietic cell transplantation (\"HCT\"), \n commonly referred to as bone marrow transplantation. The study will take \n place at the Rabin Medical Center, Beilinson, and Rambam Health Care \n Campus, Haifa, in Israel. Completion of this study will take \n approximately eight months, and is required by the FDA prior to the \n initiation of a pivotal Phase 3 study. Results of the study are expected \n by Q3 2018. Following completion of the Phase 2 study, the Company will \n initiate the Phase 3 study as quickly as possible.\n \n \n GVHD is a multisystem disorder that is a common, life-threatening \n complication of hematopoietic stem cell transplant procedures. GVHD \n occurs when the transplanted donor cells attack the patient's organs, \n including the skin, gastrointestinal tract, liver, lungs and eyes. GVHD \n is associated with acute and chronic illness, infections, disability, \n reduced quality of life and death.\n \n \n There are currently few options avai...